Abstract
Background/Aims E-cigarettes are frequently used by people who smoke. This study examined how the prevalence and patterns of smoking and vaping (‘dual use’) in England have changed as the vaping market has rapidly evolved.
Design Representative monthly cross-sectional survey, July 2016 to April 2024.
Setting England.
Participants 128,588 adults (≥18y).
Measurements Logistic regression estimated associations between survey wave and dual use. Descriptive statistics were used to analyse patterns of smoking and vaping, overall and by sociodemographic, smoking, and vaping characteristics and harm perceptions of e-cigarettes vs. cigarettes.
Results Across the period, the overall prevalence of dual use increased non-linearly from 3.5% to 5.3% of adults (prevalence ratio [PR]=1.49 [1.25-1.76]). Among adults who smoked, the proportion who also vaped was relatively stable up to mid-2021, at an average of 18.6% between July-2016 and May-2021, then increased rapidly to 34.2% by April 2024 (PR=1.76 [1.48-2.09]). This increase was greatest at younger ages (e.g., from 19.6% to 59.4% among 18-24-year-olds; PR=3.04 [2.28-4.23]). The most common pattern of dual use across the period was daily cigarette smoking with daily vaping (49.0% [47.3-50.8%]). Over time, the proportion of dual users reporting daily cigarette smoking with non-daily vaping decreased (from 35.2% to 15.0%; PR=0.43 [0.29-0.63]), offset primarily by an increase in the proportion reporting non-daily cigarette smoking with daily vaping (from 7.6% to 21.5%; PR=2.84 [1.71-4.72]). Daily cigarette smoking with daily vaping was more common (and non-daily cigarette smoking with daily vaping less common) among dual users who were older, less advantaged, mainly smoked hand-rolled cigarettes, had stronger urges to smoke, and had been vaping for ≤6 months. Daily vaping was more common among dual users who thought e-cigarettes were less/equally harmful as cigarettes, or were unsure.
Conclusions The proportion of smokers in England who vape has increased rapidly since 2021, which was when disposable e-cigarettes started to become popular. Since 2016, patterns of dual use have shifted away from more frequent smoking towards more frequent vaping. This may be the result of increasing prevalence of dual use among younger adults, who are more likely than older dual users to smoke non-daily and vape daily.
Competing Interest Statement
JB has received unrestricted research funding from Pfizer and J&J, who manufacture smoking cessation medications. LS has received honoraria for talks, unrestricted research grants and travel expenses to attend meetings and workshops from manufactures of smoking cessation medications (Pfizer; J&J), and has acted as paid reviewer for grant awarding bodies and as a paid consultant for health care companies. All authors declare no financial links with tobacco companies, e-cigarette manufacturers, or their representatives.
Clinical Protocols
Funding Statement
This work was supported by Cancer Research UK (PRCRPG-Nov21\100002). For the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for the STS was granted originally by the UCL Ethics Committee (ID 0498/001). The data are not collected by UCL and are anonymised when received by UCL.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Declaration of interests: JB has received unrestricted research funding from Pfizer and J&J, who manufacture smoking cessation medications. LS has received honoraria for talks, unrestricted research grants and travel expenses to attend meetings and workshops from manufactures of smoking cessation medications (Pfizer; J&J), and has acted as paid reviewer for grant awarding bodies and as a paid consultant for health care companies. All authors declare no financial links with tobacco companies, e-cigarette manufacturers, or their representatives.
Pre-registration: https://osf.io/pqadf/
Table 2 was not fully visible. We have reformatted this page to correct this.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
